Producing a bespoke medicine to target the unique tumor characteristics of each patient offers much promise and could be a game changer in how we treat cancer. However, bringing INT medicines to individuals in need will require addressing a broad set of new challenges for a diverse group of health system stakeholders. This panel will explain what INT is, introduce some of the unique challenges and opportunities it presents and discuss potential solutions needed to bring the promise of INT to patients.